Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device

Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant.

Athlone, Ireland–based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0